Healthcare-associated infections (HAIs) pose a significant and often preventable risk to patient safety and healthcare system sustainability. These infections, acquired during a hospital stay or medical procedure, can lead to increased morbidity, mortality, and extended hospital stays, placing a substantial economic burden on healthcare facilities. The introduction of Chlorhexidine Gluconate (CHG) wipes has been a game-changer in the fight against HAIs. These wipes are not merely a convenient alternative to traditional antiseptic solutions; they represent a major advancement in infection control protocols. By providing a standardized, single-use, and highly effective method for skin antisepsis, CHG wipes ensure consistent application and coverage, which is often difficult to achieve with traditional methods. The powerful, long-lasting antimicrobial action of CHG reduces the microbial load on a patient's skin, a critical step in preventing infections at their source. Numerous clinical studies have demonstrated a direct correlation between the use of CHG wipes for daily patient bathing and a significant reduction in the incidence of infections such as MRSA and VRE. This proactive approach to hygiene has become a cornerstone of patient safety initiatives worldwide. The efficacy and ease of use of these wipes have made them a preferred choice for healthcare professionals committed to providing the safest possible care. For a more detailed breakdown of the market dynamics and the clinical evidence supporting the use of these products, you can find a comprehensive report on the Amniotic Membrane Market.